Default company panoramic image

rheon medical

Rheon develops first-in-class glaucoma drainage device (GDD), which is externally adjustable to achieve optimal intraocular pressure (IOP).

  • Stage Concept Only
  • Industry Medical Devices and Equipment
  • Location Chemin de Pierrefleur, Lausanne, VD, Switzerland
  • Currency CHF

Company Summary

Rheon capitalizes on emerging trend of treating glaucoma with aqueous shunt technology. All current glaucoma drainage devices are passive devices, providing no control on the drainage rate. They all suffer from high complication rates (>30%), resulting from hypotony (lower than optimal pressure) in the early post-surgery period. Rheon’s shunt, the only externally adjustable device, provides optimal pressure control, eliminating all complications.


  • Default avatar
    Nikos Stergiopulos

    • Nikos Stergiopoulos, PhD is professor of bioengineering at EPFL. He is a global expert in bio-fluidics and telemetric control and has been a successful entrepreneur, founding EndoArt, Antlia, and Rheon Medical.